688076.SHG Sinopep-Allsino Biopharmaceutical Co. Ltd. A
- Market cap
- CNY 8.50B
- P/E
- 37.3x
- P/B
- 2.58x
- ROE
- 13.9%
- Dividend yield
- 2.82%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688076.SHG undervalued?
Graham number688076.SHG trades 106.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sinopep-Allsino Biopharmaceutical Co. Ltd. A fundamental analysis
No fundamental analysis for Sinopep-Allsino Biopharmaceutical Co. Ltd. A yet.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers custom peptide synthesis, custom oligo synthesis, conjugate synthesis, FTE, GMP peptides, oligonucleotide NCEs, generic APIs, formulation services, quotation request, research peptide quote, GMP peptide quote, oligonucleotide quote services. The company was…
Full company profileSinopep-Allsino Biopharmaceutical Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.51M | 229M | 256M | 372M | 567M | 644M | 651M | 1.03B | 1.62B | 1.94B | 2.33B |
| Gross Profit | 2.17M | 138M | 147M | 192M | 317M | 338M | 343M | 589M | 1.05B | 1.94B | 1.34B |
| Operating Income | -75.7M | 56.6M | 31.4M | 49.6M | 144M | 128M | 125M | 190M | 448M | 400M | 815M |
| EBITDA | -58.8M | 83.4M | 64.9M | 103M | 230M | 214M | 231M | 321M | 675M | 554M | 581M |
| Net Income | -74.8M | 41.9M | 43.9M | 48.6M | 123M | 115M | 129M | 163M | 404M | 327M | 447M |
| EPS | -0.91 | 0.26 | 0.23 | 0.21 | 0.55 | 0.43 | 0.44 | 0.54 | 1.31 | 1.04 | 1.41 |
| Balance Sheet | |||||||||||
| Total Assets | 160M | 611M | 1.05B | 1.24B | 1.40B | 2.13B | 2.52B | 3.55B | 5.08B | 6.74B | 7.19B |
| Total Liabilities | 125M | 290M | 265M | 406M | 430M | 318M | 597M | 1.36B | 2.40B | 3.74B | 3.96B |
| Shareholders' Equity | 35.0M | 321M | 778M | 834M | 963M | 1.81B | 1.91B | 2.17B | 2.66B | 2.99B | 3.22B |
| Cash & Short-term Investments | 1.79M | 24.4M | 192M | 58.1M | 150M | 679M | 443M | 749M | 779M | 914M | 941M |
| Total Debt | 106M | 132M | 88.9M | 201M | 252M | 83.6M | 320M | 850M | 1.51B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -22.0M | 11.1M | 96.1M | 46.1M | 141M | 181M | 29.3M | 350M | 400M | 681M | - |
| Capital Expenditure | 11.1M | 73.3M | 197M | 276M | 111M | 233M | 438M | 661M | 1.09B | 1.37B | 684M |
| Free Cash Flow | -33.1M | -62.2M | -101M | -230M | 30.1M | -52.6M | -409M | -310M | -690M | -686M | 266M |
| Ratios | |||||||||||
| ROE | -214.0% | 13.1% | 5.6% | 5.8% | 12.8% | 6.4% | 6.8% | 7.5% | 15.2% | 11.0% | 13.9% |
| ROA | -46.7% | 6.9% | 4.2% | 3.9% | 8.8% | 5.4% | 5.1% | 4.6% | 8.0% | 4.9% | 6.2% |
| Net Profit Margin | -879.0% | 18.3% | 17.2% | 13.1% | 21.8% | 17.9% | 19.8% | 15.8% | 24.9% | 16.8% | 19.2% |
| Debt to Equity | 3.03x | 0.41x | 0.11x | 0.24x | 0.26x | 0.05x | 0.17x | 0.39x | 0.57x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A dividends
- Dividend yield
- 2.82%
- Forward dividend
- 0.35 CNY
- Payout ratio
- 73.3%
- Ex-dividend date
- Jun 12, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 240M | 0.76 | 73.3% |
| 2024 | CNY 119M | 0.39 | 29.4% |
| 2023 | CNY 57.6M | 0.19 | 35.4% |
| 2022 | CNY 32.0M | 0.11 | 24.8% |
| 2021 | CNY 6.04M | 0.02 | 5.2% |
| 2020 | CNY 11.6M | 0.05 | 9.4% |
| 2019 | CNY 4.47M | 0.02 | 9.2% |
| 2018 | 8.38M | 0.04 | 19.1% |
| 2017 | 59.1M | 0.37 | 141.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 12, 2025.
Who owns Sinopep-Allsino Biopharmaceutical Co. Ltd. A
- Insiders 44.40%
- Institutions 0.42%
- Public & others 55.19%
- Shares outstanding 316M
- Free float 183M
Sinopep-Allsino Biopharmaceutical Co. Ltd. A company profile
- Company name
- Sinopep-Allsino Biopharmaceutical Co. Ltd. A
- Ticker
- 688076.SHG
- ISIN
- CNE1000051X5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,360
- Fiscal year end
- December
- Address
- No. 1378 Wenyi West Road, Hangzhou, China, 311121
- Phone
- 86 571 8867 1216
- Website
- sinopep.com
About Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers custom peptide synthesis, custom oligo synthesis, conjugate synthesis, FTE, GMP peptides, oligonucleotide NCEs, generic APIs, formulation services, quotation request, research peptide quote, GMP peptide quote, oligonucleotide quote services. The company was founded in 2009 and is headquartered in Hangzhou, China.
Sinopep-Allsino Biopharmaceutical Co. Ltd. A management
6- Mr. Ziquan TongGM & Chairman · born 1970
- Mr. Wei DingFinancial Director · born 1983
- Mr. Xiaohua LiSenior Vice President · born 1981
- Mr. Guoqiang ShiSenior Vice President · born 1961
- Ms. Zhou HuaSecretary of Board · born 1978
- Dr. Jianjun Jiang Ph.D.Vice President · born 1956